← Back to Search

SGLT2 Inhibitor

Dapagliflozin 10 MG [Farxiga] for Kidney Failure

Phase 4
Waitlist Available
Led By Hiddo JL Heerspink
Research Sponsored by George Clinical Pty Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights

Study Summary

This study is evaluating whether a drug called dapagliflozin might help lower blood sugar levels in people with type 2 diabetes.

Eligible Conditions
  • Kidney Failure
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in 24-hr sodium excretion

Side effects data

From 2018 Phase 4 trial • 30 Patients • NCT03006471
20%
Cervicovaginal infection
13%
Urinary tract infections
100%
80%
60%
40%
20%
0%
Study treatment Arm
Dapagliflozin
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
Patients will receive dapagliflozin 10 mg tablets once daily for 14±1 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dapagliflozin
FDA approved

Find a Location

Who is running the clinical trial?

George Clinical Pty LtdLead Sponsor
13 Previous Clinical Trials
21,275 Total Patients Enrolled
Ground Zero PharmaceuticalsIndustry Sponsor
2 Previous Clinical Trials
57 Total Patients Enrolled
University Medical Center GroningenOTHER
718 Previous Clinical Trials
979,900 Total Patients Enrolled
2 Trials studying Kidney Failure
1,541 Patients Enrolled for Kidney Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function
2021. "An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04620590.
All > Type 2 Diabetes
~4 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top